Gymnema (Herb/Suppl)

Brand and Other Names:asclepias geminate, gurmar, more...gurmarbooti, Gymnema sylvestre, merasingi, meshavalli, periploca of the woods, sirukurinja, small Indian ipecac
  • Print

Suggested Dosing

Diabetes

200-400 mg standardized extract PO qDay-BID

Use only with regular blood glucose level monitoring

Next:

Suggested Uses

Diabetes mellitus, type 1 and 2

Constipation, digestive stimulant, diuresis, lipid lowering

Efficacy

Decr blood glucose & HgbA1C in type 1 or 2 DM

Previous
Next:

Interactions

Interaction Checker

and Gymnema

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (0)

              Serious - Use Alternative (0)

                Monitor Closely (0)

                  Minor (33)

                  • acarbose

                    gymnema increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.

                  • carbonyl iron

                    gymnema decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • chlorpropamide

                    gymnema increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • ferric maltol

                    gymnema decreases levels of ferric maltol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • ferrous fumarate

                    gymnema decreases levels of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • ferrous gluconate

                    gymnema decreases levels of ferrous gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • ferrous sulfate

                    gymnema decreases levels of ferrous sulfate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • glimepiride

                    gymnema increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.

                  • glipizide

                    gymnema increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • glyburide

                    gymnema increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin aspart

                    gymnema increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin detemir

                    gymnema increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin glargine

                    gymnema increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin glulisine

                    gymnema increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin lispro

                    gymnema increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin NPH

                    gymnema increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.

                  • insulin regular human

                    gymnema increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.

                  • iron dextran complex

                    gymnema decreases levels of iron dextran complex by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • iron sucrose

                    gymnema decreases levels of iron sucrose by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • metformin

                    gymnema increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.

                  • miglitol

                    gymnema increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.

                  • nateglinide

                    gymnema increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • pioglitazone

                    gymnema increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.

                  • polysaccharide iron

                    gymnema decreases levels of polysaccharide iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • repaglinide

                    gymnema increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • rose hips

                    gymnema decreases levels of rose hips by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

                  • rosiglitazone

                    gymnema increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.

                  • saxagliptin

                    gymnema increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

                  • shark cartilage

                    shark cartilage increases effects of gymnema by pharmacodynamic synergism. Minor/Significance Unknown. Enhanced blood sugar lowering effects (theoretical interaction).

                  • sitagliptin

                    gymnema increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

                  • tolazamide

                    gymnema increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • tolbutamide

                    gymnema increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.

                  • vildagliptin

                    gymnema increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

                  Previous
                  Next:

                  Adverse Effects

                  Frequency Not Defined

                  None reported

                  Previous
                  Next:

                  Warnings

                  Contraindications

                  Hypersensitivity

                  Pregnancy

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: X

                  Lactation: N/A

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Metabolism: N/A

                  Excretion: N/A

                  Mechanism of Action

                  Decrease intestinal absorption of glucose; may stimulate pancreatic beta cell growth

                  Incr serum C-peptide levels

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.